ArticleDiabetes, obesity & metabolism2026
Time to Insulin Initiation Among Patients With Type 2 Diabetes Treated With Second-Line Antidiabetic Drugs.
Article in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Time to Insulin Initiation Among Patients With Type 2 Diabetes Treated With Second-Line Antidiabetic Drugs.Diabetes, obesity & metabolism · 2026Article
- Incident chronic kidney disease risk and the predictive value of the uric acid-to-HDL ratio in lean and non-lean MASLD: a prospective cohort and multi-omics study.International urology and nephrology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo examine the effect of second-line treatments (insulin secretagogues, thiazolidinediones, glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose co-transporter 2 (SGLT-2) inhibitors) on time to insulin initiation among patients with type 2 diabetes. RESEARCH DESIGN AND
methodsWe conducted a retrospective cohort study using the Clinical Practice Research Datalink (CPRD) Aurum. Initiation of metformin monotherapy (1998-2021) defined base cohort entry, and initiation of second-line treatment (2013-2021) defined study cohort entry (time zero). After propensity score trimming, we applied inverse probability of treatment weighted Cox models to estimate the association between second-line agents and time to insulin initiation. The secondary outcome was time to treatment modification, defined as the addition of or switch to another antidiabetic drug class.
resultsOur analytic cohort included 64 404 patients; 44% initiated DPP-4 inhibitors, 36% insulin secretagogues, 18% SGLT-2 inhibitors, 1% thiazolidinediones and 3% GLP-1 receptor agonists. Over a mean follow-up of 2.9 years, initiation of TZDs, DPP-4 inhibitors, or SGLT-2 inhibitors was associated with a lower risk of insulin initiation than initiation of insulin secretagogues (HR [95% CI]: 0.59 [0.43-0.83], 0.75 [0.69-0.80] and 0.62 [0.56-0.68], respectively). For treatment modification, the risk was higher among TZD and DPP-4 inhibitor initiators, and slightly lower among SGLT-2 inhibitor initiators and GLP-1 receptor agonist initiators than among insulin secretagogue initiators.
conclusionThis study provides real-world evidence that TZDs, DPP-4 inhibitors and SGLT-2 inhibitors may offer an advantage over insulin secretagogues in delaying insulin initiation after metformin monotherapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.